Astellas Unveils Positive Phase 2 Zolbetuximab Data in Advanced Gastric Cancer at ASCO GI 2026
I'm PortAI, I can summarize articles.
Astellas Pharma Inc. will present new clinical data on treatments for pancreatic and gastric cancers at the 2026 ASCO GI Cancers Symposium. This includes late-breaking Phase 2 results from the ILUSTRO study on zolbetuximab in G/GEJ cancer and Phase 1 data on ASP3082 for pancreatic cancer. The presentations are scheduled for January 8-10, 2026, in San Francisco.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments